drcampos
★    

Brazil,
2007-07-25 19:21
(6486 d 09:34 ago)

Posting: # 940
Views: 5,333
 

 truncated AUC [NCA / SHAM]

Post reply
Dear Helmut,

Articles and Guidances have said that the use of truncated area under the curve could be a significant advantage for BE studies of drugs with long half-lives and low intrasubject variability. So, I would like to know why is not truncated AUC a good option to high intrasubject variability drug?

Regards,

Daniel Rossi de Campos
Brazil
 
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2007-07-25 19:39
(6486 d 09:15 ago)

@ drcampos
Posting: # 941
Views: 4,160
 

 truncated AUC

Post reply
Dear Daniel,

I don’t see any reason why a truncated AUC should not be applied for a HVD/HVDP.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
91 visitors (0 registered, 91 guests [including 6 identified bots]).
Forum time: 04:55 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5